2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1579 Impact of incomplete remission on complications and outcomes of acute myeloid leukemia patients receiving non-intensive induction

Serena Tharakan, MD, Sarra Yekta2, Justin Kaner, MD3, Michael Samuel, MD4, Pinkal Desai, MD, MPH5, Ellen Ritchie, MD6, Michal Bar-Natan, MD7, Gail J Roboz, MD8, Jonathan Canaani, MD9
1 Weill Cornell Medicine, New York, New York, United States
2 Weill Cornell Medicine, New York, New York, United States
3 Weill Cornell Medicine, New York, New York, United States
4 Weill Cornell Medicine, New York, New York, United States
5 Weill Cornell Medicine, New York, New York, United States
6 Weill Cornell Medicine, New York, New York, United States
7 Weill Cornell Medicine, New York, New York, United States
8 Weill Cornell Medicine, New York, New York, United States
9 Weill Cornell Medicine, New York, New York, United States

Introduction: Complete remission (CR) has historically been the treatment goal in acute myeloid leukemia (AML). However, increasing evidence suggests patients who achieve less stringent response criteria may still receive significant clinical benefit, such as comparable transfusion independence and time to severe infection or bleeding (Le et al., Blood 2024). Previous publications in intensively treated patients showed CR to be superior to complete remission with partial hematologic recovery (CRh) and complete remission with incomplete count recovery (CRi) in terms of overall survival (OS) (Appelbaum et al., Leukemia 2024). It is unclear whether this is true for patients receiving non-intensive induction, a question of particular importance in this typically older and less fit population. In addition, prior studies have not characterized important treatment considerations in this group, such as infectious complications and rates of allogeneic stem cell transplant, with regard to remission status. Here, we compare CR with a composite of less stringent criteria (sub-CR) including CRh, CRi, and morphologic leukemia-free state (MLFS), in patients treated with non-intensive induction regimens.

Methods: This was a single-center retrospective study of 100 adult patients with newly diagnosed AML between 2021 and 2025 treated with non-intensive chemotherapy regimens at the NewYork Presbyterian/Weill Cornell Medical Center. Non-intensive regimens were primarily hypomethylating agent in combination with venetoclax. Bone marrow biopsy at the end of cycle one was used to determine CR, CRh, CRi, or MLFS. Risk was assigned by the European LeukemiaNet (ELN) 2024 less-intensive therapy classification. Survival was analyzed by Kaplan-Meier with log-rank testing; continuous variables were assessed by Cox regression. All statistical analyses were performed in R version 4.2.1 or later (R Foundation for Statistical Computing, Vienna, Austria).

Results: Median age at diagnosis was 76 years (range 20–89); 58% of patients were male. Most patients had ELN 2024 favorable-risk disease (55%), with 26% intermediate risk and 19% adverse risk. The majority had de novo AML (68%); 12% had antecedent myelodysplastic syndrome, 10% antecedent myeloproliferative neoplasm, 3% antecedent chronic myelomonocytic leukemia, and 6% another prior hematologic malignancy. NPM1 mutations were present in 17% of patients, FLT3 mutations (ITD and TKD) in 20%, and tumor suppressor mutations (TP53, WT1, PHF6) in 30%. Additional mutation classes included signaling (53%), epigenetic/chromatin (68%), cohesin (10%), RNA splicing (40%), and transcription factor (46%). Thirty- and sixty-day mortality were 3% and 8%.
After cycle one, 30% of patients had refractory/persistent disease. CR was achieved in 30 patients and sub-CR in 35 patients, comprising CRh (8%), CRi (16%), and MLFS (11%). Five patients lacked a bone marrow biopsy for response assessment and were excluded from subsequent analyses.
Baseline characteristics, including age, sex, molecular stratification, and ELN 2024 risk, did not differ between the CR and sub-CR groups. Relapse rates were similar between groups (60% vs. 46%, p=0.25), as were rates of consolidative allogeneic transplant (29% vs. 19%, p=0.37). Infectious complications during induction were also comparable between the CR and sub-CR groups, including bacteremia (28% vs. 20%, p=0.48), viral infection (10% vs. 6%, p=0.65), and ICU admission for infection (10% vs. 3%, p=0.32). Rates of intubation and vasopressor use for infection did not differ by remission status, and only one infection-related death occurred overall, in the sub-CR group. Patients achieving CR trended toward improved OS relative to those achieving sub-CR, but this difference did not reach statistical significance (median OS 38.2 vs. 26.2 months, p=0.43). One-year OS was 93% in both groups; 2-year OS was 80% vs. 65%, and 4-year OS was 25% vs. 11%, in the CR vs. sub-CR groups, respectively.

Conclusions: Among newly diagnosed adult AML patients treated with non-intensive chemotherapy, overall survival did not differ significantly between CR and sub-CR (CRh, CRi, or MLFS). Rates of consolidative allogeneic transplant and induction-related infections were likewise similar between groups. Though limited by modest subgroup sizes, these findings suggest sub-CR may confer clinical benefit comparable to CR in this setting. Larger multicenter studies are warranted.

Serena Tharakan, MD: No relevant conflicts of interest to declare.